International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia - data from the I-CAH registry
Ali, S. R.
Yavas Abalı, Z.
Bachega, T. A.
Costa, E. C.
Elsedfy, H. H.
Claahsen-van der Grinten, H. L.
Hannema, S. E.
Higham, Claire E
van der Kamp, H. J.
Krone, R. E.
Mendonca, B. B.
Miranda, M. C.
Tomlinson, J. W.
de Vries, L.
Ahmed, S. F.
Ross, R. J.
Krone, N. P.
AffiliationI Bacila, Oncology and Metabolism, The University of Sheffield, Sheffield, S10 2TN
MetadataShow full item record
AbstractObjective: Despite published guidelines no unified approach to hormone replacement in congenital adrenal hyperplasia (CAH) exists. We aimed to explore geographical and temporal variations in the treatment with glucocorticoids and mineralocorticoids in CAH. Design: This retrospective multi-center study, including 31 centers (16 countries), analyzed data from the International-CAH Registry. Methods: Data was collected from 461 patients aged 0-18 years with classic 21-hydroxylase deficiency (54.9% females) under follow-up between 1982 - 2018. Type, dose and timing of glucocorticoid and mineralocorticoid replacement was analyzed from 4174 patient visits. Results: The most frequently used glucocorticoid was hydrocortisone (87.6%). Overall, there were significant differences between age groups with regards to daily hydrocortisone-equivalent dose for body surface, with the lowest dose (median with interquartile range) of 12.0 (10.0 - 14.5) mg/ m2/ day at age 1 - 8 years and the highest dose of 14.0 (11.6 - 17.4) mg/ m2/ day at age 12-18 years. Glucocorticoid doses decreased after 2010 in patients 0-8 years (p<0.001) and remained unchanged in patients aged 8-18 years. Fludrocortisone was used in 92% of patients, with relative doses decreasing with age. A wide variation was observed among countries with regards to all aspects of steroid hormone replacement.
CitationBacila I, Freeman N, Daniel E, Sandrk M, Bryce J, Ali SR, et al. International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia - data from the I-CAH registry. Eur J Endocrinol. 2021.
JournalEuropean Journal of Endocrinology
- Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia.
- Authors: Ng SM, Stepien KM, Krishan A
- Issue date: 2020 Mar 19
- Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
- Authors: Völkl TM, Simm D, Beier C, Dörr HG
- Issue date: 2006 Jan
- Current Management and Outcome of Pregnancies in Women With Adrenal Insufficiency: Experience from a Multicenter Survey.
- Authors: Bothou C, Anand G, Li D, Kienitz T, Seejore K, Simeoli C, Ebbehoj A, Ward EG, Paragliola RM, Ferrigno R, Badenhoop K, Bensing S, Oksnes M, Esposito D, Bergthorsdottir R, Drake W, Wahlberg J, Reisch N, Hahner S, Pearce S, Trainer P, Etzrodt-Walter G, Thalmann SP, Sævik ÅB, Husebye E, Isidori AM, Falhammar H, Meyer G, Corsello SM, Pivonello R, Murray R, Bancos I, Quinkler M, Beuschlein F
- Issue date: 2020 Aug 1
- Semen quality and testicular adrenal rest tumour development in 46,XY congenital adrenal hyperplasia: the importance of optimal hormonal replacement.
- Authors: Rohayem J, Bäumer LM, Zitzmann M, Fricke-Otto S, Mohnike K, Gohlke B, Reschke F, Jourdan C, Müller HL, Dunstheimer D, Weigel J, Jorch N, Müller-Rossberg E, Lankes E, Gätjen I, Richter-Unruh A, Hauffa BP, Kliesch S, Krumbholz A, Brämswig J
- Issue date: 2021 Apr
- Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy.
- Authors: Sellick J, Aldridge S, Thomas M, Cheetham T
- Issue date: 2018 Sep 25